First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis

Tao, Jiahao; Zheng, Chuangjie; Zhang, Cuifen; Zhou, Ling; Liu, Zeyu; Zhou, Yuan; Huang, Xu-Feng; Lin, Lizhu; Zhai, Linzhu

doi:10.1177/03000605221132703

Cited by 4 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The LTK is a tyrosine kinase, which is very similar in structure to the anaplastic lymphoma kinase (ALK) [ 7 ]. The ALK kinase is a known target in cancer therapy [ 10 ], and the available medicines targeting ALK might also target the LTK.…”

Section: Introductionmentioning

confidence: 99%

“…Drug repurposing is an important direction in using developing medicines to treat new diseases by targeting the same or different pathways [ 11 , 12 , 13 ]. While a lot of drug repurposing research was made focusing on anti-viral drug treatments and combinations [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ], here, we focused on drugs approved to treat ALK-positive cancers (alectinib, ceritinib, crizotinib, brigatinib, entrectinib, lorlatinib [ 10 ]) to target ALK-negative but LTK-positive mature B cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tyrosine Kinase Inhibitors Target B Lymphocytes

et al. 2023

View full text Add to dashboard Cite

Autoimmune disorders and some types of blood cancer originate when B lymphocytes malfunction. In particular, when B cells produce antibodies recognizing the body’s proteins, it leads to various autoimmune disorders. Additionally, when B cells of various developmental stages transform into cancer cells, it results in blood cancers, including multiple myeloma, lymphoma, and leukemia. Thus, new methods of targeting B cells are required for various patient groups. Here, we used protein kinase inhibitors alectinib, brigatinib, ceritinib, crizotinib, entrectinib, and lorlatinib previously approved as drugs treating anaplastic lymphoma kinase (ALK)-positive lung cancer cells. We hypothesized that the same inhibitors will efficiently target leukocyte tyrosine kinase (LTK)-positive, actively protein-secreting mature B lymphocytes, including plasma cells. We isolated CD19-positive human B cells from the blood of healthy donors and used two alternative methods to stimulate cell maturation toward plasma cells. Using cell proliferation and flow cytometry assays, we found that ceritinib and entrectinib eliminate plasma cells from B cell populations. Alectinib, brigatinib, and crizotinib also inhibited B cell proliferation, while lorlatinib had no or limited effect on B cells. More generally, we concluded that several drugs previously developed to treat ALK-positive malignant cells can be also used to treat LTK-positive B cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Tyrosine Kinase Inhibitors Target B Lymphocytes

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Drug repurposing is an important direction in using developing medicines to treat new diseases by targeting the same or different pathways [11][12][13]. While a lot of drug repurposing research was made focusing on anti-viral drug treatments and combinations [14][15][16][17][18][19][20][21][22], here, we focused on drugs approved to treat ALK-positive cancers (alectinib, ceritinib, crizotinib, brigatinib, entrectinib, lorlatinib [10]) to target ALK-negative but LTKpositive mature B cells.…”

Section: Introductionmentioning

confidence: 99%

Tyrosine kinase inhibitors target B cells

Oksenych

2023

Preprint

View full text Add to dashboard Cite

Autoimmune disorders and some types of blood cancer originate when B lymphocytes malfunction. In particular, when B cells produce antibodies recognizing the body proteins, it leads to various autoimmune disorders. And when B cells of various developmental stages transform into cancer cells, it results in blood cancers, including multiple myeloma, lymphoma, and leukemia. Thus, new methods of targeting B cells are required for various patient groups. Here, we used protein kinase inhibitors alectinib, brigatinib, ceritinib, crizotinib, entrectinib, and lorlatinib previously approved as drugs treating anaplastic lymphoma kinase (ALK)-positive lung cancer cells. We hypothesized that the same inhibitors would efficiently target leukocyte tyrosine kinase (LTK)-positive, actively protein-secreting mature B lymphocytes, including plasma cells. We isolated CD19-positive human B cells from the blood of healthy donors and used two alternative methods to stimulate cell maturation toward plasma cells. Using cell proliferation and flow cytometry assays, we found that ceritinib and entrectinib eliminate plasma cells from B cell populations. Alectinib, brigatinib, and crizotinib also inhibited B cell proliferation, while lorlatinib had no or limited effect on B cells. More generally, we concluded that several drugs previously developed to treat ALK-positive malignant cells can also be used to treat LTK-positive B cells.

show abstract

Malignant pleural effusion diagnosis and therapy

Yang

Wang

2023

Open Life Sciences

View full text Add to dashboard Cite

Malignant pleural effusion (MPE) is a serious complication of advanced tumor, with relatively high morbidity and mortality rates, and can severely affect the quality of life and survival of patients. The mechanisms of MPE development are not well defined, but much research has been conducted to gain a deeper understanding of this process. In recent decades, although great progress has been made in the management of MPE, the diagnosis and treatment of MPE are still major challenges for clinicians. In this article, we provide a review of the research advances in the mechanisms of MPE development, diagnosis and treatment approaches. We aim to offer clinicians an overview of the latest evidence on the management of MPE, which should be individualized to provide comprehensive interventions for patients in accordance with their wishes, health status, prognosis and other factors.

show abstract

First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis

Cited by 4 publications

References 41 publications

Tyrosine Kinase Inhibitors Target B Lymphocytes

Tyrosine Kinase Inhibitors Target B Lymphocytes

Tyrosine kinase inhibitors target B cells

Malignant pleural effusion diagnosis and therapy

Contact Info

Product

Resources

About